Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 5, 2017. The filing discloses the entry into a material definitive agreement with MacAndrews & Forbes Group LLC (the "Investor"), a significant shareholder holding approximately 78.2% of the Company's combined voting power.
Key Financial Metrics and Transaction Details
- Agreement Type: Letter Agreement for a committed equity purchase facility.
- Maximum Commitment: $10.0 million aggregate amount of Class A common stock.
- Purchase Price: $4.38 per share (average volume-weighted price of the five preceding trading days).
- Investment Period: One year from the date of the agreement.
- Warrants Issued: 198,267 warrants exercisable at $5.04 per share (115% of the option price) until December 5, 2024.
- Financial Performance: The filing does not provide revenue, profit, cash flow, margin, or debt metrics.
Material Changes and Transaction Structure
The Company entered into an agreement allowing it to request the Investor to purchase shares on demand during the Investment Period. Additionally, the Investor retains the option to purchase shares at the same price up to three times during the period. The obligation to fund and issue shares is contingent upon the execution of mutually acceptable definitive documentation at the time of a funding request. This transaction was approved under the Company's Related Person Transactions Policy due to the Investor's significant ownership and shared directors.
Guidance, Risks, and Contingencies
- Contingency: The issuance of shares and funding are not automatic; they require the execution of definitive documentation upon a request for funding.
- Regulatory Status: The securities will be issued in reliance on an exemption under Regulation D of the Securities Act of 1933.
- Related Party Risk: Three Company directors are employees of the Investor, necessitating related party transaction approvals.
- Outlook: The filing does not contain specific financial guidance or management commentary on future operational performance.
Key Facts for Investor Verification
- Verify the execution of definitive documentation required to trigger any funding under the $10.0 million commitment.
- Confirm the dilution impact of the potential issuance of up to $10.0 million in shares plus 198,267 warrants.
- Review the Company's cash position to assess the immediate necessity of exercising the option to sell shares.
- Monitor the Investor's existing 78.2% voting power and the potential for further concentration of ownership.